Application of A105T mutated GABRG2 gene in preparation of epilepsy animal model
By introducing the A105T mutation GABRG2 gene in mice, an animal model similar to human epilepsy encephalopathy was constructed, which solved the problem of failure to effectively explore the pathogenesis of epilepsy in the existing technology, and achieved in-depth research on the pathogenesis of epilepsy and The basis of anti-epileptic drug screening provides value for clinical research.
Patent Information
- Application Number
- CN202411171440.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-12
AI Technical Summary
The existing technology has not yet effectively explored the epilepsy pathogenesis induced by GABRG2 mutations, and the lack of a transgenic animal model with the same variant gene background as clinical patients, limiting the in-depth understanding of the pathogenesis of epilepsy and the development of therapeutic strategies.
By introducing the A105T mutation GABRG2 gene in mice, a homologous recombination technology was used to construct an epilepsy animal model, and relevant gene knock-in, screening and verification were carried out to establish a transgenic mouse model with a phenotype similar to human epileptic encephalopathy.
An animal model similar to human epileptic encephalopathy was successfully constructed to study the pathogenesis of epilepsy and provide basic and clinical research application value for screening or preparing antiepileptic drugs.
Smart Images

Figure CN118923626A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of animal model preparation in biological and basic medical research, and specifically relates to the application of an A105T mutated GABRG2 gene in preparing an epilepsy animal model. Background Art
[0002] Epilepsy is the most common chronic neurological disease in childhood, characterized by repeated unprovoked seizures (intervals of more than 24 hours), the unknown nature of each seizure, and the long-term nature of drug treatment. At the cellular level, it manifests as excessive excitation caused by abnormal discharges of neuronal clusters. Epilepsy is divided into primary and secondary types according to the cause, of which primary epilepsy is often related to genetic defects.
[0003] The GABRG2 gene is located on chromosome 5q34 and is a member of the GABAA receptor heteropentameric ligand-gated ion channel gene family. The receptor acts as a channel for chloride ions across the cell membrane, which contributes to the hyperpolarization of the postsynaptic membrane potential and inhibits the generation of action potentials. GABRG2 mutations are often associated with autosomal dominant epilepsy. Although some studies have explored the relationship between epilepsy genotype and phenotype induced by different GABRG2 mutations, the mechanism is still unclear.
[0004] The GABRG2 (A106T) missense mutation found in clinical children is one of the many mutations in the GABRG2 gene. The mutation is located in the β1-β2 loop of the N-terminal domain of the GABAA receptor γ2 subunit, and the 316th base changes from G to A, that is, the 106th amino acid changes from alanine (A) to threonine (T). Most of these carriers develop epileptic seizures in childhood, accompanied by clinical manifestations such as hypotonia, nystagmus, intellectual disability, speech and developmental delay.
[0005] In vitro cell-level studies have found that when HEK293T cells are transfected with the GABRG2 (A106T) mutant, the expression of the γ2 subunit on the cell membrane surface is reduced, which reduces the GABA current of the cell and affects the channel function. The mechanism may be that the inhibitory function of GABA is reduced by destroying the important domain of the GABAA receptor function, thereby inducing neurological diseases such as epilepsy.
[0006] After amino acid sequence alignment, it was found that the mutation site of human GABRG2 (A106T) corresponds to the 105th amino acid of mouse. Establishing a transgenic animal model with the same mutation gene background as clinical patients is important for a deeper understanding of its pathogenesis, and can also provide new treatment strategies for patients with epileptic encephalopathy. Summary of the invention
[0007] In view of the deficiencies of the prior art, the present invention provides the use of the A105T mutated GABRG2 gene in preparing an epilepsy animal model to study the pathogenesis of existing hereditary epilepsy.
[0008] The present invention is achieved through the following technical solutions:
[0009] Application of A105T mutated GABRG2 gene in preparing animal model of epilepsy.
[0010] Preferably, the A105T mutated GABRG2 gene is a human GABRG2 gene in which the base G in the 106th amino acid Pro codon is mutated to A, and its nucleotide sequence is shown in SEQ ID NO.1.
[0011] A method for constructing a mouse epilepsy model comprises the following steps:
[0012] Step 1) using the principle of homologous recombination, the A105T mutation of the human GABRG2 gene was site-specifically knocked into the mouse GABRG2 gene, and after obtaining positive clones, a mutant gene targeting vector was obtained;
[0013] Step 2) After targeting the mutant gene targeting vector to ES cells, positive ES cells containing the mutant gene are obtained; the positive ES cells are amplified and then injected into mouse blastocysts, and the blastocysts containing the positive ES cells are then transferred into surrogate mice for breeding to obtain F0 generation chimeric mice containing the GABRG2 gene with the A105T mutation;
[0014] Step 3) The F0 generation chimeric male mice are mated with female mice to obtain F1 generation mice containing the GABRG2 gene with the A105T mutation.
[0015] Preferably, the nucleotide sequence of the mutant gene targeting vector in step 1) is as shown in SEQ ID NO.2.
[0016] Preferably, the ES cell targeting process in step 2) is as follows: the mutant gene targeting vector is transfected into ES cells by electroporation; G418 antibiotic is then used for screening, and positive clones are obtained in combination with PCR technology.
[0017] Application of the mouse epilepsy model obtained by the above construction method in epilepsy pathology research.
[0018] Application of the mouse epilepsy model obtained by the above construction method in screening or preparing anti-epileptic drugs.
[0019] The beneficial effects of the present invention are as follows:
[0020] (1) The present invention observed the phenotype of the A105T mutant GABRG2 transgenic mouse model and verified it through related experiments: PCR test was used to prove that it had a positive mutation. Water maze test, elevated maze test, open field test and other tests were used to observe the differences between mutant mice and wild-type mice in memory, cognition, emotion and other aspects. PTZ stimulation was then used to induce epileptic seizures, and the cortical electroencephalogram was recorded to analyze the susceptibility of GABRG2 mutant mice to related stimuli that induced epileptic seizures. The experimental results showed that the A105T mutant GABRG2 transgenic mouse had a phenotype similar to human epileptic encephalopathy, abnormal neurobehavior, abnormal brain discharge, and the GABRG2 (A105T) mutation had no significant effect on the development of the mouse heart, liver, spleen, lung and kidney, and was proven to be a successful animal model of epilepsy.
[0021] (2) Another object of the present invention is to provide an application of a mouse epilepsy model that can be used for basic scientific research and clinical application research. Based on the GABRG2 mutant mouse epilepsy model, the biochemical, molecular biological and genetic mechanisms related to the onset of epilepsy can be studied, and it can also be used to screen or prepare anti-epileptic drugs, which has great basic and clinical research application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 This is a schematic diagram of constructing transgenic mice using homologous recombination technology in Example 1;
[0023] Figure 2 The homologous recombination vector plasmid (A) and the enzyme digestion identification electrophoresis diagram (B) in Example 1;
[0024] Figure 3 The agarose gel electrophoresis results of the PCR products for the identification of the mutant mouse genotype in Example 1 are shown in Figure 1: A is the peak diagram of the mutant mouse sequencing; B is the agarose gel electrophoresis results of the PCR products for the identification of the mutant mouse genotype, wherein lanes 3, 4, 5, 6, 9, 10, and 19 are positive, and M is DNA Ladder (2000 bp);
[0025] Figure 4 The continuous body weight measurement records of the mutant mice in Example 1 from 11 to 24 weeks;
[0026] Figure 5 Behavior analysis of mutant mice in the Morris water maze test in Example 2: A is the swimming behavior trajectory of mice in the Morris water maze test; B is the number of times the mice found the platform (n=8, * P<0.05); C is the latency of mice to find the platform for the first time (n=8, * P<0.05);
[0027] Figure 6Behavior analysis of mutant mice in the open field test in Example 2: A is the trajectory of mouse open field behavior; B is the total distance traveled by the mouse (n=14, * P<0.05); C is the number of times mice entered the central area (n=14, * P<0.05);
[0028] Figure 7 The behavior analysis of the mutant mice in the elevated plus maze test in Example 2 is as follows: A is a graph of the mouse elevated plus maze behavior trajectory (horizontally for open arms, vertically for closed arms); B is the ratio of the time spent in the open arms OT%=OT / (OT+CT)×100% (OT: time in the open arms; CT: time in the closed arms) (n=14); C is the ratio of the number of times the mouse enters the open arms OE%=OE / (OE+CE)×100% (OE: number of times entering the open arms; CE: number of times entering the closed arms) (n=14, * P<0.05); D is the speed at which mice enter the closed arm (n=14, *** P < 0.001; E is the number of times the mouse entered the closed arm (n = 14, *** P<0.001);
[0029] Figure 8 Behavior analysis of mutant mice in the novel object recognition test in Example 2: A is the total number of times the mice explored the new and old objects (n=15); B is the total distance the mice explored the new and old objects (n=15); C is the total time the mice explored the new and old objects (n=15);
[0030] Fig. 9 The electroencephalograms of mutant mice in Example 2 before and after PTZ injection and epileptic seizures: A is a selection of mouse electroencephalograms; B is a quantitative analysis of the maximum amplitude of brain waves (n=4, *** P<0.001);
[0031] Fig.10 This is the histomorphological analysis of the mutant mice in Example 3;
[0032] Fig.11 This is the immunofluorescence staining of mutant mouse tissue in Example 3. DETAILED DESCRIPTION
[0033] The present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.
[0034] Unless otherwise specified, the technical means used in the following examples are all conventional means well known to those skilled in the art, and the experimental methods without specifying the specific conditions are all conventional methods in the art.
[0035] The experimental animals used in the following examples were constructed by Saiye Biotechnology Co., Ltd. using C57BL / 6J mice through ES gene targeting technology and are of SPF (Specific pathogen free) grade.
[0036] Example 1
[0037] The method involved in this embodiment is to knock in the GABRG2 (A105T) gene in situ, such as Figure 1 As shown, the GABRG2 (A105T) gene is a human GABRG2 gene in which the base G in the 106th amino acid Pro codon is mutated to A, and its nucleotide sequence is shown in SEQ ID NO. 1. The specific steps are as follows:
[0038] (1) Construction of ES cell targeting plasmid containing 5' homology arm, 3' homology arm and MC1 TK polyA negative selection marker.
[0039] Use restriction endonucleases or gene sequencing to verify the targeting plasmid. Figure 2 As shown in A, a targeting plasmid was constructed. To ensure the correctness of the sequence, restriction endonucleases and gene sequencing were used to verify the target sequence. The nucleotide sequence of the mutant gene targeting vector is shown in SEQ ID NO.2. The enzyme digestion reaction system was configured as shown in Table 1. The system was mixed and placed in a 37°C water bath. After reacting for 2 hours, an appropriate amount of Gel loading buffer was added and mixed, and then agarose gel electrophoresis was performed. After the bands were separated, photos were taken ( Figure 2 Middle B). The plasmid verified by restriction digestion was sent to a sequencing company for sequencing.
[0040] Table 1 Enzyme digestion reaction system
[0041]
[0042] (2) After the targeting plasmid is linearized, ES cell targeting is performed. The targeting vector is homologously recombined with the C57BL / 6N mouse ES cell genome to obtain gene-recombined ES cells containing the A105T mutant GABRG2, and resistant ES cells are obtained by G418 pressure screening. Positive ES cell clones with correct homologous recombination of both arms are screened by PCR and sequencing. Positive ES cell clones containing the mutant gene are injected into blastocysts to obtain chimeric male mice.
[0043] The obtained ES cell clones were screened using PCR technology. The cells electroporated with the positive targeting vector were transferred to a culture dish pre-seeded with G418-resistant MEF cells, and the mouse embryonic stem cell serum culture medium (OriCell, MUXES-90011) was used for subsequent culture and screening. After the drug screening was completed, the surviving clones were picked into a 96-well plate, one clone per well, and the culture medium was changed every day. On the third day after the clone was picked, the 96-well plate was propagated in two, and one of them was frozen after the cells were full. After the other cell was full, the genomic DNA was extracted for subsequent PCR identification.
[0044] (3) The chimeric male mice were mated with Flp female mice, and the offspring were genotyped to obtain F1 mice with positive Neo gene deletion, among which the positive A105T mice were obtained.
[0045] Genotype identification of F1 generation GABRG2 (A105T) mice: Genomic DNA of offspring mice was extracted and polymerase chain reaction (PCR) was performed. The PCR system is shown in Table 2, and the PCR program is shown in Table 3. The specific information of the primer pairs used is as follows:
[0046] Primer F (SEQ ID NO.3): 5'-GGTCATTGGGGAAGATTTTGATTCG-3';
[0047] Primer R (SEQ ID NO. 4): 5'-CGGAAGCTGTTTGTGATTCCTGAC-3'.
[0048] Table 2 PCR system
[0049]
[0050] Table 3 PCR program
[0051]
[0052] The identification results are as follows Figure 3 As shown, the positive PCR product of A105T mice is a positive band of about 309 bp, while the positive PCR product of WT mice is a band of 190 bp.
[0053] (4) Measure the body weight of mice at 8 weeks of age. Figure 4 As shown, the body weight of GABRG2(A105T) mice was significantly lower than that of WT controls, suggesting that GABRG2 mutation may cause developmental delay in mice.
[0054] Example 2
[0055] The mice prepared in Example 1 were subjected to behavioral experiments. All experimental mice were age-matched mice and were divided into GABRG2 (A105T) mice and WT mice. All behavioral experiments were completed at Nantong University, and the experimental animal ethics requirements were strictly followed throughout the experiment.
[0056] 1. Morris water maze test
[0057] The test lasted for 5 days, of which the first to fourth days were the learning phase, and the fifth day was the testing phase. The water maze cylinder (specification 1.5m) used for testing mice was divided into four quadrants. Before the training began, the water temperature was adjusted to 18-22°C in advance, and non-toxic white pigment should be added to the water to facilitate the identification of mice. During the experiment, blackout curtains and indirect light sources should be used to avoid light interference with image acquisition. The platform was placed in the first quadrant. During the learning phase, the training was scheduled for 4 times a day at a fixed time period. On the first day, the mice were placed in the water from the middle of the first, second, third, and fourth quadrants in a counterclockwise manner, facing the pool wall, and observed for 60 seconds. If the mouse finds the platform, the timing ends until it stays on the platform for 10 seconds, and the experiment ends. If the mouse does not stay on the platform for 10 seconds after finding the platform, the timing continues until the observation time accumulates to 60 seconds. If the mouse does not find the platform at the end of the timing, the experimenter should guide it to help it find the platform. On the second day, the mice were placed in the water from the middle of the second, first, fourth, and third quadrants in a clockwise manner, with their backs to the pool wall; on the third day, the mice were placed in the water from the middle of the third, fourth, first, and second quadrants in a counterclockwise manner, with their backs to the pool wall; on the fourth day, the mice were placed in the water from the middle of the fourth, third, second, and first quadrants in a clockwise manner, with their backs to the pool wall. Each animal was trained 4 times a day, with an interval of 15 to 20 minutes between two training sessions, and the training lasted for 4 consecutive days. During the test phase, the platform was removed, and the mice were placed in the water from the middle of the third quadrant pool wall with their backs to the pool wall, and the activity of the mice was tested within 60 seconds.
[0058] The experimental results are as follows Figure 5 As shown, the time it takes GABRG2(A105T) mice to find the platform ( Figure 5 Middle B), the number of times you cross the platform ( Figure 5 C) were less than those in WT mice, suggesting that the cognitive and memory functions of these mice were decreased.
[0059] 2. Open field test
[0060] Before the experiment, the animals were allowed to adapt to the testing environment for 60 minutes, and the experimental box was kept clean and odorless. The experimental animals were gently taken out of the cage, with their backs facing the experimenter, and quickly placed in the central area of the experimental box, and then left immediately. The activities of the animals in the box were recorded. The experimental time was 10 minutes.
[0061] The experimental results are as follows Figure 6As shown, GABRG2(A105T) mice had reduced movement distance and speed in the open field compared with WT mice ( Figure 6 Middle B), the time to enter the central area is reduced ( Figure 6 Middle C), showing that GABRG2(A105T) mice exhibit depressive-like behaviors.
[0062] 3. Elevated plus maze test
[0063] Take the experimental animal out of the cage, with its back facing the experimenter as far as possible, and gently place the animal in the central area of the instrument body with the animal facing the open arms. Open the animal behavior analysis software and track the animal's movement trajectory in the elevated cross maze instrument. The experiment lasts for 5 minutes.
[0064] The experimental results are as follows Figure 7 As shown in the figure, the total number of entries into the open arm and the closed arm (OE+CE) represents the motor activity of the mice. The results showed that there was no significant difference in the proportion of open arm residence time (OT%) of GABRG2(A105T) mice compared with the WT control group ( Figure 7 B), but the proportion of entering the open arm (OE%) was significantly reduced ( Figure 7 Middle C), GABRG2(A105T) mice spent time in the closed arms ( Figure 7 D) and number of entries ( Figure 7 Middle E) is significantly less than that of WT mice, revealing different anxiety behaviors of GABRG2(A105T) mice from WT mice.
[0065] 4. Novel Object Recognition
[0066] 24 hours before the test, place the animals in the test room to adapt to the test environment. At the beginning of training, place objects A and B at the left and right ends of one side wall, and put the mouse into the field with its back facing the two objects. The distance between the tip of the mouse's nose and the two objects should be the same. Leave the mouse for 5 minutes, and record the contact between the mouse and the two objects, including the number of times the nose or mouth touches the objects and the time spent exploring within 2 to 3 cm from the objects. After the test, immediately put the mouse back into the original mouse box, and let the mouse rest for 1 hour before testing again. When the test starts again, replace object B in the field with object C, and still place the mouse with its back facing the two objects, with the tip of the nose at the same distance from the two objects. Observe the mouse's exploration of object C within 5 minutes.
[0067] The experimental results are as follows Figure 8 As shown, there was no difference in novel object exploration between GABRG2(A105T) mice and WT mice.
[0068] 5. EEG recording of pentylenetetrazol (PTZ)-induced epileptic seizures
[0069] Epidural electrodes with stainless steel screws and multi-strand copper wires were prepared. Before implanting the electrodes, the mice were anesthetized and erythromycin ointment was used to prevent retinitis. After the mouse skin was disinfected, a 1.5 cm incision was made along the midline of the brain to expose the skull. Three holes were drilled with a small handheld skull drill, one hole was located 1.5 mm in front of the front upper (left), one was located 3 mm in front of the back lower (right), and the other hole was placed 3 mm behind the back lower (left) as a fixed electrode, each hole was located 1.5 mm outside the central sulcus, and a stainless steel micro screw with a diameter of 1.2 mm was welded to a multi-strand copper wire with a diameter of 0.28 mm as an epidural electrode and fixed to the skull with dental acrylic adhesive. Seven days after the electrode was implanted, video EEG was recorded for 30 minutes using a biomedical signal acquisition and processing system. Then 40 mg / kg PTZ was injected intraperitoneally to continue video EEG recording for 30 minutes.
[0070] The experimental results are as follows Fig. 9 As shown, GABRG2(A105T) mice had higher frequency and amplitude EEG images before and after PTZ induction.
[0071] The experimental results of this example show that the GABRG2 (A105T) mouse obtained by the construction method of Example 1 has a phenotype similar to human epileptic encephalopathy, abnormal neurobehavior, and abnormal brain discharge, and is proven to be a successful animal model of epilepsy.
[0072] Example 3
[0073] 1. Histomorphological analysis of GABRG2(A105T) mice
[0074] Hematoxylin-eosin (HE) staining: The GABRG2 (A105T) mouse tissues were embedded, and after embedding, the paraffin tissues were cut into 5 μm thickness and attached to the slides; the cut tissues were placed in a 65°C oven for more than 6 hours; the baked tissues were stained with HE.
[0075] The experimental results are as follows Fig.10 As shown in the figure, compared with the WT control group, there was no significant difference in the arrangement and spacing of myocardial fibers in GABRG2(A105T) mice; the liver structure was normal, the boundaries were clear, and the hepatocyte nuclei were centered without significant differences; there was no significant difference in the number of red pulp cells in the spleen; the lung structure was clear, and no obvious lesions were found in the alveoli; the volume and morphology of the glomeruli and renal tubules in the kidneys had no obvious pathological characteristics. The above results indicate that the GABRG2(A105T) mutation has no significant effect on the development of the mouse heart, liver, spleen, lung, and kidney.
[0076] 2. Immunofluorescence staining analysis of GABRG2(A105T) mouse tissues
[0077] (1) Frozen sections: After taking the sample, place it in 4% paraformaldehyde (prepared and used immediately), and then change to 10% sucrose (prepared in PB) for dehydration after 24 hours, then change to 20% sucrose (prepared in PB) for dehydration after 24 hours, and then change to 30% sucrose (prepared in PB) for dehydration after 24 hours. Dehydration is successful when the tissue sinks to the bottom of the centrifuge tube. After taking out the tissue and laying it flat, drip embedding agent around it, quickly place it on the freezing table and freeze it. Drip embedding agent, slice it with a thickness of 10μm and stick it on a clean slide. Place the cut tissue slide in a slice box and dry it at 37℃ for 2 hours.
[0078] (2) Tissue immunofluorescence staining: Use an immunohistochemical pen to circle the tissue on the tissue slide. Wash with PBS three times, 10 minutes each time. Block with blocking solution at room temperature for 1.5 hours. Add the diluted primary antibody to the brain tissue, cover with a sealing clip, and incubate at 4°C overnight. Wash with PBS three times, 10 minutes each time. Add the corresponding fluorescent secondary antibody to the brain slice and incubate at 37°C for 1.5 hours. Discard the secondary antibody and wash with PBS three times, 10 minutes each time. Add sealing solution and cover the tissue with a coverslip (after adding the secondary antibody, it must be handled in a dark place). Take pictures using a laser confocal microscope.
[0079] The experimental results are as follows Fig.11 As shown, the expression and localization of GABRG2 in the mouse hippocampus tissue were observed by immunofluorescence staining, and neurons were labeled with β-tublin III. Compared with the WT control group, the fluorescence intensity of GABRG2 was significantly weakened, indicating that the GABRG2 (A105T) mutation led to a significant downregulation of GABRG2 expression in the mouse brain.
[0080] The experimental results of the above examples show that the GABRG2 (A105T) mouse obtained by the construction method of Example 1 has a phenotype similar to human epileptic encephalopathy, neurobehavioral abnormalities, abnormal brain discharges, and the GABRG2 (A105T) mutation has no significant effect on the development of the mouse heart, liver, spleen, lung, and kidney. It can be used as an effective animal model of epilepsy for studying the biochemical and molecular biological and genetic mechanisms related to the onset of epilepsy, and can also be used for screening or preparing anti-epileptic drugs, and has great basic and clinical research application value.
[0081] The embodiments described above are only some embodiments of the present invention, rather than all embodiments. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but merely represents selected embodiments of the present invention. The scope of protection of the present invention shall be subject to the scope required by the claims. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work shall fall within the scope of protection of the present invention.
Claims
1. Application of A105T mutated GABRG2 gene in preparing epilepsy animal model.
2. The use according to claim 1, characterized in that: The A105T mutated GABRG2 gene is a human GABRG2 gene in which the base G in the 106th amino acid Pro codon is mutated to A, and its nucleotide sequence is shown in SEQ ID NO.
1.
3. A method for constructing a mouse epilepsy model, characterized in that: The following steps are involved: Step 1) using the principle of homologous recombination, the A105T mutation of the human GABRG2 gene was site-specifically knocked into the mouse GABRG2 gene, and after obtaining positive clones, a mutant gene targeting vector was obtained; Step 2) After targeting the mutant gene targeting vector to ES cells, positive ES cells containing the mutant gene are obtained; the positive ES cells are amplified and then injected into mouse blastocysts, and the blastocysts containing the positive ES cells are then transferred into surrogate mice for breeding to obtain F0 generation chimeric mice containing the GABRG2 gene with the A105T mutation; Step 3) The F0 generation chimeric male mice are mated with female mice to obtain F1 generation mice containing the GABRG2 gene with the A105T mutation.
4. The method for constructing a mouse epilepsy model according to claim 3, characterized in that: Step 1) The nucleotide sequence of the mutant gene targeting vector is shown in SEQ ID NO.
2.
5. The method for constructing a mouse epilepsy model according to claim 3, characterized in that: Step 2) The ES cell targeting process is as follows: the mutant gene targeting vector is transfected into ES cells by electroporation; G418 antibiotic is then used for screening, and positive clones are obtained in combination with PCR technology.
6. Application of the mouse epilepsy model obtained by the construction method according to any one of claims 3 to 5 in epilepsy pathology research.
7. Use of the mouse epilepsy model obtained by the construction method according to any one of claims 3 to 5 in screening or preparing anti-epileptic drugs.
Citation Information
Patent Citations
Construction of mouse model of idiopathic basal ganglia calcification-causing gene mutation
CN110551691A
Construction method and application of zebra fish intractable epilepsy model
CN111304251A
Construction method for mutant gabrg2 transgenic zebrafish epilepsy model and applications
WO2020228305A1
